From the clinical observation that ceftriaxone treatment can decrease the volume of unexpected MYCN‐driven RB, we demonstrate that ceftriaxone similarly has antitumoral activities in RB and NB cells and is a potent growth inhibitor of MYCN‐amplified tumor cells. The gene discussed is MYCN; the disease is neoplasm.